Enanta Pharmaceuticals - ENTA Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ENTA shares.
View ENTA analyst ratings or view top-rated stocks.

9 brokers have issued twelve-month price targets for Enanta Pharmaceuticals' stock. Their ENTA share price forecasts range from $49.00 to $96.00. On average, they expect the company's share price to reach $68.60 in the next year. This suggests a possible upside of 76.7% from the stock's current price.
View analysts price targets for ENTA or view top-rated stocks among Wall Street analysts.

Enanta Pharmaceuticals' stock was trading at $46.52 at the beginning of the year. Since then, ENTA stock has decreased by 16.6% and is now trading at $38.82.
View the best growth stocks for 2023 here.

Enanta Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 900,100 shares, an increase of 20.0% from the February 28th total of 750,300 shares. Based on an average daily volume of 168,700 shares, the short-interest ratio is presently 5.3 days. Approximately 4.7% of the company's shares are short sold.
View Enanta Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our ENTA earnings forecast.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) posted its earnings results on Tuesday, February, 7th. The biotechnology company reported ($1.39) EPS for the quarter, beating analysts' consensus estimates of ($1.52) by $0.13. The biotechnology company had revenue of $23.60 million for the quarter, compared to analyst estimates of $22.48 million. Enanta Pharmaceuticals had a negative net margin of 146.93% and a negative trailing twelve-month return on equity of 36.59%. Enanta Pharmaceuticals's quarterly revenue was down 14.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.48) earnings per share.

ETFs with the largest weight of Enanta Pharmaceuticals (NASDAQ:ENTA) stock in their portfolio include Invesco Dynamic Pharmaceuticals ETF (PJP), Virtus LifeSci Biotech Products ETF (BBP), ETFMG Treatments Testing and Advancements ETF (GERM), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (9.95%), Dimensional Fund Advisors LP (2.60%), Renaissance Technologies LLC (2.27%), Geode Capital Management LLC (1.81%), Braidwell LP (1.56%) and Norges Bank (1.08%). Insiders that own company stock include Bruce L A Carter, Jay R Luly, Nathalie Adda, Paul J Mellett and Yat Sun Or.
View institutional ownership trends.

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ENTA stock can currently be purchased for approximately $38.82.

Enanta Pharmaceuticals (NASDAQ:ENTA) has a market capitalization of $810.79 million and generates $82.10 million in revenue each year. The biotechnology company earns $-121,750,000.00 in net income (profit) each year or ($5.82) on an earnings per share basis.

The company employs 155 workers across the globe.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.enanta.com. The biotechnology company can be reached via phone at (617) 607-0800, via email at cmiceli@enanta.com, or via fax at 617-607-0530.